Streetbeat News

ESTA

Establishment Labs Holdings Inc.

https://www.establishmentlabs.com

Industry

Medical - Devices

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Establishment Labs shares are trading higher following the announcement that the Center for Devices and Radiological Health has completed its review of the company's premarket approval application for Motiva Implants. The application is deemed approvable pending an acceptable FDA inspection of the company's manufacturing facilities.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 1:46 pm

The FDA's Center for Devices and Radiological Health has completed its review of Establishment Labs' premarket approval application for Motiva Implants. The application is deemed approvable pending an acceptable FDA inspection of the manufacturing facilities, which has been rescheduled to occur within the next thirty days.

Portfolio Pulse from Benzinga Newsdesk

June 05, 2024 | 11:13 am

Analysts have provided mixed ratings for Establishment Labs Hldgs (NASDAQ:ESTA) over the past quarter, with a range of opinions from bullish to bearish. The average 12-month price target has increased to $59.6, reflecting a 16.86% rise from the previous target. Despite positive analyst actions, the company faces financial challenges, including a decline in revenue growth and high debt levels.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 1:00 pm

Citigroup analyst Joanne Wuensch has downgraded Establishment Labs Holdings (NASDAQ:ESTA) from Buy to Neutral, while maintaining the price target at $60.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 12:48 pm

Establishment Labs Holdings (ESTA) reported Q1 2024 adjusted EPS of $(0.58), surpassing the $(0.67) estimate, with sales of $37.200M exceeding the $36.001M forecast. This represents a 20.04% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

May 08, 2024 | 8:03 pm

Today's session highlighted significant whale activity in the health care sector, focusing on options trading for stocks like MRK, PFE, CVS, AZN, IBRX, MRNA, ESTA, UNH, BAX, and HUM. The trades varied in sentiment from bullish to bearish, with notable investments in both call and put options across various expiration dates and strike prices. This activity could indicate market expectations and potential movements in these stocks.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 5:35 pm

Establishment Labs Holdings Inc. (NASDAQ:ESTA) announced the presentation of four-year results from the Motiva US IDE Study at The Aesthetic Meeting 2024. The study, which focuses on breast aesthetics and reconstruction, showed high patient compliance and low complication rates over four years. Dr. Caroline Glicksman presented the data, highlighting the consistency of clinical results and the potential for Motiva implants to set a new standard in breast implants in the U.S. The Motiva Implant PMA is currently under FDA review, with the implants not yet approved for commercial distribution in the United States.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 12:35 pm

Today's whale activity in the Health Care sector highlighted significant options trading across various stocks, indicating bullish, bearish, and neutral sentiments. Notable trades were observed in UNH, MRNA, TMDX, ESTA, NVCR, GILD, ABBV, VKTX, INSP, and CI, with varying expiration dates, strike prices, and sentiments. This activity could signal upcoming movements in these stocks based on the large sums of money involved and the sentiments expressed through these option trades.

Portfolio Pulse from Benzinga Insights

April 03, 2024 | 5:35 pm

Citigroup analyst Joanne Wuensch has maintained a Buy rating on Establishment Labs Holdings (ESTA) and increased the price target from $49 to $60.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:46 pm

Establishment Labs Holdings (NASDAQ:ESTA) has seen a positive shift in analyst ratings over the past three months, with a recent average price target of $56.25, up 15.57% from the previous $48.67. Analysts from Mizuho, TD Cowen, JP Morgan, and Stephens & Co. have raised their price targets, reflecting optimism about the company's future performance. Despite this, the company faces challenges with a -27.97% revenue decline, a net margin of -65.09%, and a high debt-to-equity ratio of 10.45, indicating potential financial leverage concerns.

Portfolio Pulse from Benzinga Insights

April 01, 2024 | 2:00 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.